Johns Hopkins Startup Neuraly Plans Phase 1 Parkinson’s Trial

(July 23, 2018) – A new startup from Johns Hopkins has launched with $36 million in financing in the pursuit of disease-modifying agents for Parkinson’s disease and other neurodegenerative disorders. The company’s pipeline is built around NLY01, a long-acting glucagon-like peptide-1 receptor agonist that penetrates the brain and has shown promise as a neuroprotective agent. Read more

Follow Us Follow us on TwitterFollow us on FacebookInstagram

Sign Up for Email Alerts

By providing your email you agree to receive periodic emails from The Parkinson Alliance.

Please tell us more about yourself:

This month is? (Anti-Spam)

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2018 The Parkinson Alliance. All rights reserved.